AMF France v. AB Science S.A. and A (false or misleading information, 2016)
Judgment entered
Checked against the primary document on October 5, 2026. The library's summary, tags and figures for this record were compared with the regulator's own document by an AI model (Claude) following written instructions, in a single reading of the French decision; an independent second reading of 60 of the AMF records agreed on every field for 54 and on the core fields for 59. No lawyer has reviewed them. A checked record can still contain errors, and checked does not mean endorsed. See how we check records or report a correction.
In June 2016 the AMF Commission des sanctions fined AB Science and its chief executive, published as A, 200,000 euros each over a share-issue draw made while an expected regulatory setback was allegedly undisclosed, and over alleged misleading press releases.
The record
| Agency | AMF (France) |
|---|---|
| Release number | SAN-2016-09 |
| Date filed | 2016-06-28 |
| Date resolved | 2016-06-28 |
| Court | Commission des sanctions (AMF, France) |
| Status | judgment |
| Asset class | equities |
| Instruments | AB Science shares |
| Venue | Euronext Paris |
| Criminal parallel | No |
| Defendants | AB Science S.A. ; A |
| Techniques | Misleading issuer disclosure |
What was ordered
- Civil penalty
- —
- Disgorgement
- —
- Prejudgment interest
- —
- Total relief
- —
- Alleged gain
- —
- Penalty as published
- €400k
What is alleged to have happened
The 1st section of the Commission des sanctions decided this case on 28 June 2016. The AMF's board had notified grievances on 21 May 2015 to the biopharmaceutical company AB Science and to its founder and chief executive, published as A. Its shares traded on compartment B of Euronext Paris.
AB Science had agreed a capital-increase programme with Société Générale under which it could issue new shares at 95% of a short-term average price. It drew on the programme on 11 November 2013, and the bank subscribed for 256,000 shares at 19.47 euros, around 4.98 million euros, and resold them within days. The AMF alleged that four press releases in early November 2013 misled the public on the valuation of the shares by omitting a risk to a flagship study, and that the company failed to disclose, from 21 October 2013, the strong likelihood of a negative opinion from the European regulator on a conditional marketing authorisation for a drug, expected on 21 November 2013.
The Commission retained a breach linked to the timing of the draw on the programme relative to the undisclosed information, and did not find it established that one of the contested releases was misleading. It noted that a draw made after the negative opinion would have priced the new shares about 29% lower. It imposed 200,000 euros on AB Science and 200,000 euros on A, a total of 400,000 euros.
The record does not show a finding of price manipulation, and it does not show whether the decision was appealed.
This library tags the matter as misleading issuer disclosure. The tagging is ours, not the regulator's.
For the regulator's own account of the facts, read the primary document linked above. This page deliberately summarises the structured record rather than reproducing the decision.
What technique is this, and how does it work?
This action is tagged with one technique in our taxonomy. The tagging is ours: regulators charge statutory provisions, not technique names, so the mapping is an editorial judgement described in our editorial policy.
- Misleading issuer disclosure — see how it works, what statute it engages, and every other action tagged the same way.
Timeline
- 2016-06-28 Commission des sanctions decision
Primary documents
Everything on this page derives from the documents below. Where our summary and the primary document disagree, the primary document is right.
Related actions
Other actions in the library sharing at least one technique tag with this one.